Estée Lauder Companies Inc. — Form 10-Q Summary
Period: The filing covers the quarter ended March 31, 2024, the third quarter of fiscal 2024, and the nine months then ended. This differs from the request metadata label “2023 Q3.” Amounts below are in millions of dollars except per-share data and percentages.
Financial performance
| Metric | Three months ended March 31, 2024 | Three months ended March 31, 2023 | Nine months ended March 31, 2024 | Nine months ended March 31, 2023 |
|---|---|---|---|---|
| Net sales | $3,940 | $3,751 | $11,737 | $12,301 |
| Gross margin | 71.9% | 69.1% | 71.6% | 72.4% |
| Operating income | $531 | $297 | $1,203 | $1,514 |
| Operating margin | 13.5% | 7.9% | 10.2% | 12.3% |
| Net earnings attributable to Estée Lauder | $330 | $156 | $674 | $1,039 |
| Diluted EPS | $0.91 | $0.43 | $1.87 | $2.88 |
Quarterly sales rose 5% reported (6% in constant currency); nine-month sales fell 5% reported (4% in constant currency). Quarterly operating income increased 79%, while nine-month operating income decreased 21%. Adjusted diluted EPS, a non-GAAP measure, was $0.97 for the quarter and $1.95 for the nine months, versus $0.47 and $3.38, respectively.
For the nine months, operating cash flow was $1,471, compared with $1,017 a year earlier; capital expenditures were $702, versus $652. Cash and cash equivalents were $3,701 at March 31, 2024, down from $4,029 at June 30, 2023. Total debt was $7,770, including $505 current and $7,265 long-term, compared with $8,114 at June 30, 2023. Total debt was 57% of total capitalization, versus 59%. Current assets were $8,534 and current liabilities $5,416.
Material changes and operating trends
- Quarterly sales improvement was led by Asia travel retail shipments, reflecting better sequential retail-sales trends and progress toward retailer inventory targets; the prior-year quarter also had transitory headwinds. Management said the nine-month comparison remained pressured by travel-retail inventory resets and weaker prestige-beauty demand in mainland China.
- Quarterly sales increased in skin care (8%) and makeup (3%); fragrance was approximately flat and hair care declined 3%. For the nine months, skin care fell 9%, makeup fell 2%, fragrance grew 2%, and hair care fell 5%.
- Quarterly gross margin expanded 280 basis points, supported by business mix, pricing and lower obsolescence charges, partly offset by manufacturing costs and foreign exchange. Nine-month gross margin contracted 80 basis points, largely due to manufacturing costs and foreign exchange.
- Quarterly operating margin improved with higher sales, gross margin and lower operating-expense ratio. Nine-month operating margin declined amid lower sales, weaker gross margin and a higher operating-expense ratio. Prior-year intangible-asset impairment charges of $207 affected the nine-month comparison; the filing’s adjusted measures also exclude restructuring and acquisition-related stock-option fair-value changes.
- Nine-month sales fell 10% by volume and rose 5% from pricing. Quarterly sales rose 10% from pricing but fell 4% by volume. These components are management’s reported sales drivers.
Outlook, risks and unusual items
- The company launched a two-year restructuring program as part of its Profit Recovery Plan, intended to rebuild margins in fiscal 2025 and 2026. It expects $500–$700 of pretax charges and annual gross benefits of $350–$500 once fully implemented; some benefits are expected to be reinvested in consumer-facing activities. The broader Profit Recovery Plan had previously identified $800–$1,000 of benefits. Estimated workforce reductions are 1,800–3,000 positions, with initiatives expected to be substantially completed through fiscal 2026.
- Management expects continued volatility, softness in mainland China prestige beauty, disruption in Israel and parts of the Middle East, and manufacturing under-absorption from lower production volumes. It also notes possible future inventory-reduction charges, inflation, currency volatility, geopolitical and supply-chain risks, and potential impairment risk if sales and profitability decline. The filing does not provide a clear full-year revenue or EPS forecast in the supplied text.
- In April 2024, the company exercised its option to purchase the remaining DECIEM interests; settlement of the redeemable noncontrolling interest and DECIEM stock options was expected in fiscal Q4. The purchase price is based on DECIEM’s performance; a clear purchase-price value is not provided.
- The July 2023 cybersecurity incident investigation concluded that an unauthorized party obtained some consumer and employee data. The filing states the incident was not expected to materially affect sales and was expected to dilute fiscal 2024 EPS by approximately $0.07 after insurance recoveries.
- A securities class action alleges misleading statements during February 2022–October 2023; the company intends to defend itself. Management says current litigation is not expected to have a material adverse effect, while noting outcomes could differ from its assessment.
- The company corrected prior-period product-category sales and operating-income classifications for comparability; it said the corrections did not affect consolidated financial statements and were not material. Management reported disclosure controls were effective as of March 31, 2024.
Key facts for investors to verify
- Whether Asia travel-retail improvement reflects durable consumer sell-through and sustainable inventory normalization, rather than shipment timing.
- Progress in mainland China, travel retail and volume trends, alongside the contribution and durability of pricing and product mix.
- Execution costs, timing and realized savings from the restructuring and broader Profit Recovery Plan, including any reinvestment of benefits.
- Cash conversion, capital spending, debt maturities and financing needs, including the DECIEM purchase price and Q4 settlement.
- Whether manufacturing under-absorption, inventory actions, currency movements, cybersecurity-related costs and legal matters develop differently from management’s expectations.